Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15662749 | 0.83 | PIK3CG (0.41) | PIK3CGKDM4EGAA | |
| SCHEMBL30281806 | 0.82 | PIK3CG (0.40) | PIK3CGKDM4EGAA | |
| SCHEMBL12410858 | 0.82 | PIK3CG (0.40) | PIK3CGKDM4EGAAIKBKB | |
| SCHEMBL28917520 | 0.82 | PIK3CG (0.40) | PIK3CGKDM4EGAA | |
| SCHEMBL25259423 | 0.80 | PIK3CG (0.39) | PIK3CGKDM4EGAA | |
| Potassium Ion SCHEMBL22659395 | 0.80 | PIK3CG (0.39) | PIK3CGKDM4EGAA | |
| Hydrochloric Acid SCHEMBL30484796 | 0.80 | PIK3CG (0.39) | PIK3CGKDM4EGAAIKBKB | |
| SCHEMBL12410863 | 0.79 | PIK3CG (0.41) | PIK3CGKDM4EGAA | |
| SCHEMBL12410864 | 0.79 | PIK3CG (0.38) | PIK3CGKDM4EGAA | |
| SCHEMBL17645642 | 0.79 | PIK3CG (0.41) | PIK3CGKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-11547698-B2 | Aryl hydrocarbon receptor modulators | ARIAGEN, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20190330201-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS | AHR PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190307731-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
| WO-2018035080-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | WO | disclosed |
| US-4760147-A | Isopropyl 1,4-dihydro-2,6-dimethyl-4-(2,3-dichlorophenyl)-3-(1,3,4-oxadiazol-2 -yl)pyridine-5-carboxylate | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| US-4681891-A | Dihydro-2,6-dimethyl pyridines, formulations and method of use for treating angina pectoris, high blood pressure or disturbances of cerebral or peripheral blood flow | CASSELLA AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
| EP-0183091-A2 | 1,4-Dihydropyridines, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1986-06-04 | — | — | EP | disclosed |
| EP-0172509-A2 | Process for the preparation of optically active, substituted 1,4-dihydropyridines and their use as medicaments | CASSELLA Aktiengesellschaft (DE) | 1986-02-26 | — | — | EP | disclosed |
| US-4558058-A | HYPOTENSIVE AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1985-12-10 | — | — | US | disclosed |
| EP-0116708-A1 | Substituted 1,4-dihydropyridines, method for their preparation and their use as pharmaceuticals | CASSELLA Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307731-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | AHR, ARNT, NR1H4 | PIK3CG 4692/4885KDM4E 2566/4885GAA 4860/4885 |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | BTK, SYK, LCK | PIK3CG 57/4885KDM4E 783/4885GAA 3416/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | PIK3CG 3435/4885KDM4E 3081/4885GAA 4532/4885 |
| US-11547698-B2 | Aryl hydrocarbon receptor modulators | AHR, ARNT, CNR1 | PIK3CG 4692/4885KDM4E 2197/4885GAA 4762/4885 |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | PIK3CG 57/4885KDM4E 783/4885GAA 3416/4885 |
| US-20190330201-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, CNR1 | PIK3CG 4692/4885KDM4E 2197/4885GAA 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.